Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 6 Comparison of training set and validation set features, n (%)

Characteristic	Training cohort, n = 84	Internal test cohort, n = 36	P value
HBV-DNA			0.749
> 2000	37 (44)	17 (47)
≤ 2000	47 (56)	19 (53)
HBV			0.001
Negative	67 (80)	18 (50)
Positive	17 (20)	18 (50)
Antiviral therapy			0.806
No	18 (21)	7 (19)
Yes	66 (79)	29 (81)
Child Pugh score			0.022
A	30 (36)	21 (58)
B	54 (64)	15 (42)
PVTT			0.780
No	42 (50)	19 (53)
Yes	42 (50)	17 (47)
BCLC stage			0.690
B	41 (49)	19 (53)
C	43 (51)	17 (47)
Metastasis			0.936
No	46 (55)	20 (56)
Yes	38 (45)	16 (44)
AFP			0.035
> 1210	48 (57)	13 (36)
≤ 1210	36 (43)	23 (64)
Sex			0.837
Female	31 (37)	14 (39)
Male	53 (63)	22 (61)
Age			0.968
< 60	44 (52)	19 (53)
≥ 60	40 (48)	17 (47)
BMI			0.333
Low	48 (57)	25 (69)
Normal	5 (6.0)	3 (8.3)
Obese	5 (6.0)	0 (0)
Overweight	26 (31)	8 (22)
ECOG			0.491
0-1	48 (57)	23 (64)
2	36 (43)	13 (36)
Post operative			0.569
No	49 (58)	23 (64)
Yes	35 (42)	13 (36)
ALT			0.262
> 40	35 (42)	19 (53)
≤ 40	49 (58)	17 (47)
Total bilirubin			0.049
> 34	62 (74)	20 (56)
≤ 34	22 (26)	16 (44)
Diabetes			0.066
No	59 (70)	31 (86)
Yes	25 (30)	5 (14)
Hypertensive			0.827
No	24 (29)	11 (31)
Yes	60 (71)	25 (69)
Cirrhosis			0.245
No	44 (52)	23 (64)
Yes	40 (48)	13 (36)
Smoking			0.365
No	56 (67)	27 (75)
Yes	28 (33)	9 (25)
Alcohol			0.228
No	51 (61)	26 (72)
Yes	33 (39)	10 (28)
Virus reactivation			0.512
No	83 (99)	35 (97)
Yes	1 (1)	1 (3)

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PVTT: Portal vein tumor thrombosis.